Drug
Eptinezumab
Eptinezumab: highest development phase Post-Market, developed by Lundbeck. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Eptinezumab NCT06701526 | Post-Market | Migraine |
| Eptinezumab NCT04965675 | Phase 3 | Chronic Migraine in Children |
| Eptinezumab NCT05164172 | Phase 3 | Migraine |
| Eptinezumab NCT04152083 | Phase 3 | Migraine |
| Eptinezumab NCT04688775 | Phase 3 | Cluster Headache, Episodic |
| Eptinezumab NCT05897320 | Phase 3 | Episodic Migraine |
| Eptinezumab NCT04537429 | Phase 1 | Migraine in Children |
| Eptinezumab NCT05045781 | Phase 1 | Healthy |
Latest
Follow Eptinezumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.